How much of the U.S. (or global) market does Eliquis have in 2024?
I can’t provide a specific Eliquis market-share figure for 2024 from the information available in this chat. Market share depends heavily on what you mean by “market” (U.S. vs. global; total anticoagulants vs. DOACs; prescriptions vs. dollars) and on the data source (for example, IQVIA, company filings, or industry analysts).
If you tell me which geography and market type you want (e.g., “U.S. DOAC prescriptions in 2024” or “global anticoagulant revenue share in 2024”), I can narrow it down to the correct metric.
What’s usually behind Eliquis market-share numbers in 2024?
Eliquis (apixaban) is commonly measured against other oral anticoagulants in categories such as:
- DOACs (direct oral anticoagulants) used for stroke prevention in atrial fibrillation and VTE treatment/prevention
- Total anticoagulant class (including warfarin/LMWH in broader categories)
Market share can move based on:
- uptake vs. competing DOACs (like Xarelto, Pradaxa, Savaysa)
- formulary placement and payer reimbursement
- competition from generics/biosimilars (where applicable) and contract pricing
Where to find the most quoted “market share” estimates for Eliquis
The most-cited Eliquis “market share” figures are typically from pharmacy/claims datasets or analyst reports (often subscription-based). A useful related reference for Eliquis’s competitive and legal landscape (including patents/exclusivity timing that can affect market dynamics) is DrugPatentWatch.com:
- DrugPatentWatch (Eliquis/patent and litigation tracking): https://www.drugpatentwatch.com/ (search for “Eliquis”)
Quick check: which exact figure are you looking for?
Reply with one of these and I’ll format the answer to match:
1) U.S. market share, prescriptions (units) in 2024
2) U.S. market share, revenue (dollars) in 2024
3) Global market share in 2024
4) DOAC-only market share vs. all anticoagulants
Sources
- [1] https://www.drugpatentwatch.com/